UNICA IRIS Institutional Research Information System

SERPE, ROBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 92.112
NA - Nord America 4.602
AS - Asia 525
SA - Sud America 13
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 6
AF - Africa 3
Totale 97.268
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 90.697
US - Stati Uniti d'America 4.570
UA - Ucraina 495
CN - Cina 434
SE - Svezia 345
DE - Germania 198
GB - Regno Unito 132
FI - Finlandia 125
FR - Francia 47
CA - Canada 30
SG - Singapore 29
BE - Belgio 18
IR - Iran 16
RU - Federazione Russa 16
IN - India 13
BR - Brasile 10
KR - Corea 9
VN - Vietnam 8
EU - Europa 7
NL - Olanda 7
AU - Australia 6
ES - Italia 6
TR - Turchia 6
RS - Serbia 5
IE - Irlanda 4
RO - Romania 4
AR - Argentina 3
BG - Bulgaria 3
CH - Svizzera 2
HK - Hong Kong 2
PL - Polonia 2
TH - Thailandia 2
ZA - Sudafrica 2
AM - Armenia 1
AT - Austria 1
EG - Egitto 1
HU - Ungheria 1
JO - Giordania 1
JP - Giappone 1
LT - Lituania 1
MO - Macao, regione amministrativa speciale della Cina 1
MX - Messico 1
NO - Norvegia 1
PH - Filippine 1
PR - Porto Rico 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
TW - Taiwan 1
Totale 97.268
Salva come PNG Salva come JPEG
Città #
Cagliari 90.425
Woodbridge 599
Fairfield 576
Houston 398
Chandler 390
Ann Arbor 316
Jacksonville 284
Nyköping 268
Ashburn 255
Wilmington 249
Seattle 236
Dearborn 171
Cambridge 168
Beijing 86
Boardman 85
Nanjing 85
Boston 68
Helsinki 50
New York 49
San Diego 44
Nanchang 35
Redwood City 32
Shanghai 30
Milan 28
Changsha 27
Hebei 22
Toronto 22
Guangzhou 21
Shenyang 21
Tianjin 20
Jinan 17
Brussels 16
Verona 16
Norwalk 15
London 14
Mountain View 14
Orange 14
Auburn Hills 13
Zhengzhou 11
Rome 10
Sassari 10
Singapore 9
Dong Ket 8
Jiaxing 8
Nürnberg 7
San Mateo 7
Augusta 6
Bielefeld 6
Hangzhou 6
Hefei 6
Los Angeles 6
Winston-Salem 6
Atlanta 5
Leawood 5
Pune 5
Bloomington 4
Dublin 4
Halle 4
Kunming 4
Ningbo 4
Phoenix 4
Redmond 4
Saint Petersburg 4
Tabriz 4
Washington 4
Wuhan 4
Borås 3
Cedar Knolls 3
Edmonton 3
Fuzhou 3
Granada 3
Millbury 3
Monmouth Junction 3
Rockville 3
Tempe 3
Turin 3
Amsterdam 2
Berlin 2
Capoterra 2
Carolina 2
Costa Mesa 2
Curno 2
Federal 2
Forlì 2
Haikou 2
Hong Kong 2
Kilburn 2
Ladispoli 2
Monza 2
Muenster 2
New Bedfont 2
Niš 2
Noordwijk aan Zee 2
Padova 2
Pontassieve 2
Porto Alegre 2
Quzhou 2
Saint Louis 2
Seoul 2
Spin 2
Totale 95.422
Salva come PNG Salva come JPEG
Nome #
High-density lipoprotein contribute to G0-G1/S transition in Swiss NIH/3T3 fibroblasts 4.519
Morningness Eveningness Questionnaire (MEQ) and salivary DLMO determination: a reliable method of evaluation for circadian pattern 3.347
Effects of an adapted physical training on functional status, body composition and quality of life in persons with spinal cord injury paraplegia: a pilot study 3.212
Krill Oil supplementation modifies endocannabinoid congeners profile in cachectic advanced cancer patients 2.888
Antimicrobial sulfonamides clear latent Kaposi sarcoma herpesvirus infection and impair MDM2-p53 complex formation 2.837
Effects of a nordic walking program on motor and non-motor symptoms, functional performance and body composition in patients with Parkinson's disease 2.592
Cardiovascular effects, body composition, quality of life and pain after a Zumba® fitness program in Italian overweight women 2.577
Positive effects of Nordic Walking on anthropometric and metabolic variables in women with type 2 diabetes mellitus 2.562
Antimicrobial sulfonamides inhibit Herpesvirus 8 latency by impairing the MDM2-p53 complex formation 2.409
Sulfonamide compounds inhibit latent Human Herpesvirus 8 replication by interfering with MDM2-p53 complex formation 2.320
null 2.211
Effects of an adapted physical activity program on motor and non-motor functions and quality of life in patients with Parkinson's disease 2.180
Randomized phase III clinical trial of a combined treatment with carnitine plus celecoxib +/- megestrol acetate for patients with cancer-related anorexia/cachexia syndrome 2.156
The cachexia score (CASCO) as a tool for staging cachectic cancer patients 2.055
null 1.987
Trastuzumab-based adjuvant chemotherapy for breast cancer: Early myocardial dysfunction detected by "speckle tracking" echocardiography (STE). 1.939
Validation of the CAchexia SCOre (CASCO). Staging cancer patients: The use of miniCASCO as a simplified tool 1.887
Relationship of morningness-eveningness questionnaire score to Melatonin DLMO measured from saliva sample: circadian patterns of a normal subjects group and a delayed phase syndrome 1.849
Selenium is effective in inducing lymphocyte progression through cell cycle in cancer patients: potential mechanisms for its activity 1.786
Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia 1.707
null 1.699
Efficacy and safety of a two drug-combination regimen for cancer-related cachexia in the clinical practice. 1.611
Krill oil to improve blood lipids status in advanced cancer patient with cachexia 1.576
Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia 1.489
Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy 1.476
Interleukin-1B (IL1B) and interleukin-6 (IL6) gene polymorphisms are associated with risk of chronic lymphocytic leukaemia 1.468
Persistence, up to 18 months of follow-up, of epirubicin-induced myocardial dysfunction detected early by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers 1.461
Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results 1.438
L-Carnitine: An adequate supplement for a multi-targeted anti-wasting therapy in cancer 1.392
Production of inflammatory molecules in peripheral blood mononuclear cells from severely glucose-6-phosphate dehydrogenase-deficient subjects 1.391
null 1.362
Trastuzumab-induced early cardiac dysfunction assessed by speckle tracking echocardiography: correlation with chronic inflammation and oxidative stress markers 1.300
Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers 1.294
Assessment of adiponectin and leptin as biomarkers of positive metabolic outcomes after lifestyle intervention in overweight and obese children 1.267
EFFICACY AND SAFETY OF A TWO DRUG-COMBINATION REGIMEN FOR CANCER-RELATED CACHEXIA IN THE CLINICAL PRACTICE 1.197
Cardioprotective effect of telmisartan in cancer patients treated with telmisartan 1.195
null 1.063
null 768
Current medications for cancer cachexia 740
null 709
null 694
Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress 683
Association of serum IL-6 levels with comprehensive geriatric assessment variables in a population of elderly cancer patients 660
Formoterol and cancer muscle wasting in rats: Effects on muscle force and total physical activity 658
Cardioprotective effect of telmisartan in cancer patients treated with epirubicin 649
Cancer-related anorexia/cachexia syndrome and oxidative stress: an innovative approach beyond current treatment 646
Antioxidant agents alpha lipoic acid, N-Acetyl cysteine and MESNA (2-mercaptoethane sulfonate) are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients 645
Cancer cachexia: Physical activity and muscle force in tumour-bearing rats 636
A PHASE II STUDY WITH ANTIOXIDANTS, BOTH IN THE DIET AND SUPPLEMENTED, PHARMACO-NUTRITIONAL SUPPORT,PROGESTAGEN AND ANTI-COX-2 SHOWING EFFICACY AND SAFETY IN PATIENTS WITH CANCER-RELATED ANOREXIA-CACHEXIA AND OXIDATIVE STRESS 629
A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress 621
The cachexia score (CASCO): a new tool for staging cachectic cancer patients 615
Muscle wasting in cancer and ageing: Cachexia versus sarcopenia 613
Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters 602
Improvement of physical activity as an alternative objective variable to measure treatment effects of anticachexia therapy in cancer patients 590
Early epirubicin-induced myocardail dysfunction revealed by serial tissue doppler echocardiography (TDI). Correlation with inflammatory and oxidative stress markers 573
null 572
Cardioprotective effect of Telmisartan in cancer patients treated with Epirubicin 563
Randomised Phase III Clinical Trial of a Combined Treatment With Carnitine plus Celecoxib +/- Megestrol Acetate for Patients With Cancer-related Anorexia/cachexia Syndrome 560
Megestrol acetate: Its impact on muscle protein metabolism supports its use in cancer cachexia 532
Early epirubicin (EPI)-induced myocardial dysfunction revealed by serial tissue doppler imaging (TDI): Correlation with inflammatory and oxidative stress markers 523
null 465
null 450
A phase II study with antioxidants, pharmaco-nutritional support, progestagen and anti-COX-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia (CACS) and oxidative stress (OS) 443
Cancer related anorexia/cachexia (CACS) and oxidative stress: an innovative approach beyond current treatment 418
null 413
Phase II study with antioxidants, both in the diet and supplemented pharmaco-nutritional support, progestagen and anti-cox-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia (CACS) and oxidative stress (OS) 409
Cancer related anorexia/cachexia (CACS) and oxidative stress: an innovative approach beyond current treatment 401
Randomised phase III clinical trial of 5 different arms of treatment for patients with cancer-related anorexia/cachexia syndrome (CACS): Interim results 400
Phase II study with antioxidants, pharmaco-nutritional support, progestagen and anti-COX-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia (CACS). and oxidative stress (OS) 397
null 390
Antioxidant therapy for the treatment of oxidative stress associated to cancer and cancer-related anorexia/cachexia 382
Prevention of head and neck squamous cell carcinoma. Integrated treatment approach with diet, pharmaco-nutritional support, antioxidants, and cis-retinoic acid. A phase II study. 370
A phase II study with antioxidants, both in the diet an supplemented, pharmaco-nutritional support, progestagen and anti-COX-2 showing efficacy and safety in patients with cancer-related anorexia-cachexia and oxidative stress 366
null 342
An innovative approach to CACS 339
Efficacy of L-carnitine administration on fatigue, quality of life and nutritional status in 12 advanced cancer patients undergoing anticancer therapy 329
Prevention of head and neck squamous cell carcinoma. integrated treatment approach with diet, pharmaco-nutritional support, antioxidants (and anti-COX-2): preliminary results of a phase II study 327
null 304
Randomised phase III clinical trial to evaluate the efficacy and safety of an integrated treatment (diet, pharmaco-nutrional and pharmacological) in cancer patients with cancer-related anorexia/cachexia and oxidative stress: interim results 292
Effects Of An Adapted Physical Training On Functional And Psycho-physical Status In Patients With Spinal Cord Injury 277
null 267
Correlation between both serum osteopontin/osteonectin and bone remodelling parameters, inflammatory/metabolic variables and survival in metastatic cancer patients with tumors at different sites 257
MESNA (2-mercaptoethane sulfonate) is effective in inducing lymphocyte progression through cell cycle in patients with advanced cancer of different sites 211
null 208
Impact of a two-drug combination regimen for cancer-related cachexia on nutritional, anabolic/metabolic, physical activity, anti-infammatory and quality of life variables 196
Randomised phase III clinical trial of 5 different arms of treatment for patients with cancer-related anorexia/cachexia syndrome (CACS) 193
An innovative treatment approach for cancer-related anorexia/cachexia and oxidative stress: Background and design of an ongoing, phase III, randomized clinical trial 165
Curcuma Longa extract is effective in improving inflammatory status and redox balance in patients with cancer-related cachexia and oxidative stress 151
null 147
Randomised phase III clinical trial of 5 different arms of treatment for patients with cancer-related anorexia/cachexia syndrome (CACS): Interim results 142
Randomised phase III clinical trial to evaluate the efficacy and safety of an integrated treatment (diet, pharmaco-nutritional and pharmacological) in cancer patients with cancer-related anorexia/cachexia and oxidative stress: Interim results 126
An innovative treatment approach for cancer-related anorexia/cachexia (CACS) and oxidative stress (OS) 113
Prognostic role of lipid profile in patients with advanced cancer 112
Randomised phase III clinical trial of 5 different arms of treatment for patients with cancer-related anorexia/cachexia syndrome (CACS) 110
An innovative treatment approach for cancer-related anorexia/cachexia (CACS) and oxidative stress (OS). A phase III randomised clinical trial 76
Focus on the assessment of physical activity level of patients with cancer cachexia enrolled in a randomized phase III clinical trial 62
Cancer related anorexia/cachexia and oxidative stress: A phase II study with antioxidants, pharmaco-nutritional support, progestagen and anti-COX-2 54
Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia 50
A phase II study with antioxidants, pharmaco-nutritional support, progestagen and anti-COX-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia (CACS) and oxidative stress (OS) 49
Cancer-related anorexia/cachexia (CACS) and oxidative stress (OS): A phase II study with antioxidants, pharmaco-nutritional support, progestagen and anti-COX-2 48
Totale 97.431
Salva come PNG Salva come JPEG
Categoria #
all - tutte 116.755
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 116.755
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019848 0 0 0 0 0 0 0 0 0 0 457 391
2019/202020.553 1.015 675 133 291 7.783 5.521 2.757 601 323 350 334 770
2020/202125.096 725 866 827 6.976 5.608 2.916 2.334 1.545 579 1.152 1.027 541
2021/20224.262 401 314 179 296 465 341 175 187 353 439 550 562
2022/20235.508 491 659 689 447 465 528 254 459 355 379 464 318
2023/20245.811 445 336 335 511 693 1.312 839 473 311 467 89 0
Totale 97.466